Against the backdrop of physiological CSPG4 expression on normal tissues, albeit at a low level, concerns may be stirred that decitabine not only increases CSPG4 expression on malignant cells but also amplifies the physiological CSPG4 expression beyond the level required for CAR activation, potentially increasing the risk for inadvertent on-target/off-tumor toxicity. Here, CSPG4 is linked to neoplasm.